Brugada Syndrome (BrS) is traditionally considered a primary channelopathy, most commonly due to reduced inward sodium current with an increased risk of syncope and sudden cardiac death (SCD). According to the recent guidelines, BrS is diag nosed in patients with ST‑segment elevation with type 1 morphol ogy among the right precordial leads V1 and V2 , occurring either spontaneously or after provocative drug test with intravenous administration of Class I antiarrhythmic drugs. Moreover, BrS is diagnosed in patients with type 2 or type 3 ST‑segment elevation in ≥1 lead among the right precordial leads when a provocative drug test with intravenous administration of Class I antiarrhyth mic drugs induces a type I ECG morphology. Risk stratification of SCD is the most important aspect of the concise management of those patients. Importantly,